Menlo Therapeutics Announces Results from a Phase 2 Clinical Trial of Serlopitant for the Treatment of Refractory Chronic Cough
Serlopitant fails to demonstrate efficacy relative to placebo on primary and secondary endpoints REDWOOD CITY, Calif., Oct. 08, 2018 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO) a late-stage biopharmaceutical company focused on the …